Interesting study regarding seroconversion (antibody development)

2,125 Views | 1 Replies | Last: 5 yr ago by DTP02
AgsMyDude
How long do you want to ignore this user?
AG
https://www.medrxiv.org/content/10.1101/2020.06.21.20132449v1

Note: preprint w/o peer review so take it with a grain of salt

Quote:

Background.

In the background of the current COVID-19 pandemic, serological tests are being used to assess past infection and immunity against SARS-CoV-2. This knowledge is paramount to determine the transmission dynamics of SARS-CoV-2 through the post pandemic period. Several individuals belonging to households with an index COVID-19 patient, reported symptoms of COVID-19 but discrepant serology results. Methods. Here we investigated the humoral and cellular immune responses against SARS-CoV-2 in seven families, including nine index patients and eight contacts, who had evidence of serological discordances within the households. Ten unexposed healthy donors were enrolled as controls.

Results.

All index patients recovered from a mild COVID-19. They all developed anti-SARS-CoV-2 antibodies and a significant T cell response detectable up to 69 days after symptom onset. Six of the eight contacts reported COVID-19 symptoms within 1 to 7 days after the index patients but all were SARS-CoV-2 seronegative. Six out of eight contacts developed a SARS-CoV-2-specific T cell response against structural and/or accessory proteins that lasts up to 80 days post symptom onset suggesting a past SARS-CoV-2 infection.

Conclusion.

Exposure to SARS-CoV-2 can induce virus-specific T cell responses without seroconversion. T cell responses may be more sensitive indicators of SARS-Co-V-2 exposure than antibodies. Our results indicate that epidemiological data relying only on the detection of SARS-CoV-2 antibodies may lead to a substantial underestimation of prior exposure to the virus

This could be potentially huge news if people are warding off severe COVID development with Tcell response and never need to produce antibodies.

Could mean we're missing part of the equation as currently we only have positive tests + antibody tests and may have even more infected than the serological studies (like in NY/Italy) have shown.
beerad12man
How long do you want to ignore this user?
AG
I don't have time this morning to look at these in detail, but could this correlate to daggers post? Both seem like good news.

I've thought for a while the trend was to shoot up really quick, and then no matter what the response was(masks/no masks, strict lockdowns, half ass lock downs, etc.) there seems to be a pattern of topping out well below what would be considered herd immunity and then a slow but steady drop.

Would also bode better for Sweden when the article came out yesterday about how herd immunity was so far away with only 6.1% having antibodies.

But I could also just be looking for good news.
DTP02
How long do you want to ignore this user?
AG
beerad12man said:

I don't have time this morning to look at these in detail, but could this correlate to daggers post? Both seem like good news.

I've thought for a while the trend was to shoot up really quick, and then no matter what the response was(masks/no masks, strict lockdowns, half ass lock downs, etc.) there seems to be a pattern of topping out well below what would be considered herd immunity and then a slow but steady drop.

Would also bode better for Sweden when the article came out yesterday about how herd immunity was so far away with only 6.1% having antibodies.

But I could also just be looking for good news.


You might be on to something. The PSU analysis makes a ton of sense from a math/statistics standpoint, but there would need to be an explanation for why we aren't seeing more testing positive for infection and antibodies.

This is obviously very preliminary at this stage, but I wonder when we could expect to to get more substantiation of this possibility.
Refresh
Page 1 of 1
 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.